The Horizons in Cancer Drug Discovery meeting brings together leaders from industry, academic/clinical cancer research and venture capital funders. The aim is to hear presentations and discuss ideas about new and existing strategies - things that work and the need for innovation - and explore the potential of alliances between academia, SMEs, Biotech, Pharma and funders.

A number of VC firms invited and the key leaders from Janssen, Eli-Lilly, AstraZenca and Novartis global oncology departments who will be presenting, as well as at the leading edge of cancer discovery science and innovative patient treatment.